Publication

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients

van den Elsen, S. H. J., Sturkenboom, M. G. G., van 't Boveneind-Vrubleuskaya, N., Skrahina, A., van der Werf, T. S., Heysell, S. K., Mpagama, S., Migliori, G. B., Peloquin, C. A., Touw, D. J. & Alffenaar, J-W. C., Dec-2018, In : Antimicrobial Agents and Chemotherapy. 62, 12, 10 p., ARTN e01092-18.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van den Elsen, S. H. J., Sturkenboom, M. G. G., van 't Boveneind-Vrubleuskaya, N., Skrahina, A., van der Werf, T. S., Heysell, S. K., ... Alffenaar, J-W. C. (2018). Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 62(12), [ARTN e01092-18]. https://doi.org/10.1128/AAC.01092-18

Author

van den Elsen, Simone H J ; Sturkenboom, Marieke G G ; van 't Boveneind-Vrubleuskaya, Natasha ; Skrahina, Alena ; van der Werf, Tjip S ; Heysell, Scott K ; Mpagama, Stellah ; Migliori, Giovanni B ; Peloquin, Charles A ; Touw, Daan J ; Alffenaar, Jan-Willem C. / Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. In: Antimicrobial Agents and Chemotherapy. 2018 ; Vol. 62, No. 12.

Harvard

van den Elsen, SHJ, Sturkenboom, MGG, van 't Boveneind-Vrubleuskaya, N, Skrahina, A, van der Werf, TS, Heysell, SK, Mpagama, S, Migliori, GB, Peloquin, CA, Touw, DJ & Alffenaar, J-WC 2018, 'Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients', Antimicrobial Agents and Chemotherapy, vol. 62, no. 12, ARTN e01092-18. https://doi.org/10.1128/AAC.01092-18

Standard

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. / van den Elsen, Simone H J; Sturkenboom, Marieke G G; van 't Boveneind-Vrubleuskaya, Natasha; Skrahina, Alena; van der Werf, Tjip S; Heysell, Scott K; Mpagama, Stellah; Migliori, Giovanni B; Peloquin, Charles A; Touw, Daan J; Alffenaar, Jan-Willem C.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 12, ARTN e01092-18, 12.2018.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van den Elsen SHJ, Sturkenboom MGG, van 't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK et al. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 2018 Dec;62(12). ARTN e01092-18. https://doi.org/10.1128/AAC.01092-18


BibTeX

@article{71e26eae69ad4049aa9b4864bc92a36b,
title = "Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients",
abstract = "Levofloxacin is an antituberculosis drug with substantial interindividual pharmacokinetic variability; therapeutic drug monitoring (TDM) could therefore be helpful to improve treatment results. TDM would be more feasible with limited sampling strategies (LSSs), a method to estimate the area under the concentration curve for the 24-h dosing interval (AUC(0-24)) by using a limited number of samples. This study aimed to develop a population pharmacokinetic (popPK) model of levofloxacin in tuberculosis patients, along with LSSs using a Bayesian and multiple linear regression approach. The popPK model and Bayesian LSS were developed using data from 30 patients and externally validated with 20 patients. The LSS based on multiple linear regression was internally validated using jackknife analysis. Only clinically suitable LSSs (maximum time span, 8 h; minimum interval, 1 h; 1 to 3 samples) were tested. Performance criteria were root-mean-square error (RMSE) of 0.95. A one-compartment model with lag time best described the data while only slightly underestimating the AUC(0-24) (mean, -7.9{\%}; standard error [SE], 1.7{\%}). The Bayesian LSS using 0- and 5-h postdose samples (RMSE, 8.8{\%}; MPE, 0.42{\%}; r(2=)0.957) adequately estimated the AUC(0-24), with a mean underestimation of -4.4{\%} (SE, 2.7{\%}). The multiple linear regression LSS using 0- and 4-h postdose samples (RMSE, 7.0{\%}; MPE, 5.5{\%}; r(2)=0.977) was internally validated, with a mean underestimation of -0.46{\%} (SE, 2.0{\%}). In this study, we successfully developed a popPK model and two LSSs that could be implemented in clinical practice to assist TDM of levofloxacin.",
keywords = "levofloxacin, pharmacodynamics, pharmacokinetics, sampling strategy, therapeutic drug monitoring, tuberculosis, DRUG, MOXIFLOXACIN, MANAGEMENT",
author = "{van den Elsen}, {Simone H J} and Sturkenboom, {Marieke G G} and {van 't Boveneind-Vrubleuskaya}, Natasha and Alena Skrahina and {van der Werf}, {Tjip S} and Heysell, {Scott K} and Stellah Mpagama and Migliori, {Giovanni B} and Peloquin, {Charles A} and Touw, {Daan J} and Alffenaar, {Jan-Willem C}",
note = "Copyright {\circledC} 2018 American Society for Microbiology.",
year = "2018",
month = "12",
doi = "10.1128/AAC.01092-18",
language = "English",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "AMER SOC MICROBIOLOGY",
number = "12",

}

RIS

TY - JOUR

T1 - Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients

AU - van den Elsen, Simone H J

AU - Sturkenboom, Marieke G G

AU - van 't Boveneind-Vrubleuskaya, Natasha

AU - Skrahina, Alena

AU - van der Werf, Tjip S

AU - Heysell, Scott K

AU - Mpagama, Stellah

AU - Migliori, Giovanni B

AU - Peloquin, Charles A

AU - Touw, Daan J

AU - Alffenaar, Jan-Willem C

N1 - Copyright © 2018 American Society for Microbiology.

PY - 2018/12

Y1 - 2018/12

N2 - Levofloxacin is an antituberculosis drug with substantial interindividual pharmacokinetic variability; therapeutic drug monitoring (TDM) could therefore be helpful to improve treatment results. TDM would be more feasible with limited sampling strategies (LSSs), a method to estimate the area under the concentration curve for the 24-h dosing interval (AUC(0-24)) by using a limited number of samples. This study aimed to develop a population pharmacokinetic (popPK) model of levofloxacin in tuberculosis patients, along with LSSs using a Bayesian and multiple linear regression approach. The popPK model and Bayesian LSS were developed using data from 30 patients and externally validated with 20 patients. The LSS based on multiple linear regression was internally validated using jackknife analysis. Only clinically suitable LSSs (maximum time span, 8 h; minimum interval, 1 h; 1 to 3 samples) were tested. Performance criteria were root-mean-square error (RMSE) of 0.95. A one-compartment model with lag time best described the data while only slightly underestimating the AUC(0-24) (mean, -7.9%; standard error [SE], 1.7%). The Bayesian LSS using 0- and 5-h postdose samples (RMSE, 8.8%; MPE, 0.42%; r(2=)0.957) adequately estimated the AUC(0-24), with a mean underestimation of -4.4% (SE, 2.7%). The multiple linear regression LSS using 0- and 4-h postdose samples (RMSE, 7.0%; MPE, 5.5%; r(2)=0.977) was internally validated, with a mean underestimation of -0.46% (SE, 2.0%). In this study, we successfully developed a popPK model and two LSSs that could be implemented in clinical practice to assist TDM of levofloxacin.

AB - Levofloxacin is an antituberculosis drug with substantial interindividual pharmacokinetic variability; therapeutic drug monitoring (TDM) could therefore be helpful to improve treatment results. TDM would be more feasible with limited sampling strategies (LSSs), a method to estimate the area under the concentration curve for the 24-h dosing interval (AUC(0-24)) by using a limited number of samples. This study aimed to develop a population pharmacokinetic (popPK) model of levofloxacin in tuberculosis patients, along with LSSs using a Bayesian and multiple linear regression approach. The popPK model and Bayesian LSS were developed using data from 30 patients and externally validated with 20 patients. The LSS based on multiple linear regression was internally validated using jackknife analysis. Only clinically suitable LSSs (maximum time span, 8 h; minimum interval, 1 h; 1 to 3 samples) were tested. Performance criteria were root-mean-square error (RMSE) of 0.95. A one-compartment model with lag time best described the data while only slightly underestimating the AUC(0-24) (mean, -7.9%; standard error [SE], 1.7%). The Bayesian LSS using 0- and 5-h postdose samples (RMSE, 8.8%; MPE, 0.42%; r(2=)0.957) adequately estimated the AUC(0-24), with a mean underestimation of -4.4% (SE, 2.7%). The multiple linear regression LSS using 0- and 4-h postdose samples (RMSE, 7.0%; MPE, 5.5%; r(2)=0.977) was internally validated, with a mean underestimation of -0.46% (SE, 2.0%). In this study, we successfully developed a popPK model and two LSSs that could be implemented in clinical practice to assist TDM of levofloxacin.

KW - levofloxacin

KW - pharmacodynamics

KW - pharmacokinetics

KW - sampling strategy

KW - therapeutic drug monitoring

KW - tuberculosis

KW - DRUG

KW - MOXIFLOXACIN

KW - MANAGEMENT

U2 - 10.1128/AAC.01092-18

DO - 10.1128/AAC.01092-18

M3 - Article

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 12

M1 - ARTN e01092-18

ER -

ID: 66811180